Abeer Alanazi: New Stroke Prevention Without Increased Bleeding Risk
Abeer Alanazi, Senior Clinical Pharmacist at King Fahad Specialist Hospital Dammam, Member of European Stroke Organisation (ESO), shared a post on LinkedIn about a recent article by Mukul Sharma et al. published in NEJM, adding:
“Here’s the biggest thing to happen to secondary stroke prevention since the advent of clopidogrel!!
The phase 3 OCEANIC-STROKE trial
In patients with recent noncardioembolic ischemic stroke or high-risk TIA, asundexian 50 mg and antiplatelet therapy reduced the risk of ischemic stroke vs placebo (6.2% vs 8.4%; HR 0.74; P<0.001)
No increase in major bleeding.”
Title: Asundexian for Secondary Stroke Prevention
Authors: Mukul Sharma, Qiang Dong, Teruyuki Hirano, Scott E. Kasner, Jeffrey L. Saver, Jaime Masjuan, Andrew M. Demchuk, Charlotte Cordonnier, Daniel Bereczki, Georgios Tsivgoulis, Roland Veltkamp, Ivan Staikov, Hee-Joon Bae, Bruce C.V. Campbell, Andrea Zini, I-Hui Lee, Martin Kovar, Robert Mikulik, Robin Lemmens, José M. Ferro, Thompson Robinson, Hanne Christensen, Serefnur Ozturk, Ronen R. Leker, Peter Turcani, Agnieszka Slowik, Pablo Amaya, Fan Kee Hoo, Gian Marco De Marchis, Michael Knoflach, P.N. Sylaja, Jukka Putaala, Jonathan M. Coutinho, H. Bart van der Worp, Evija Miglane, Vaidas Matijošaitis, Arne G. Lindgren, Gisele Sampaio Silva, Else Charlotte Sandset, Saule T. Turuspekova, Pierre Amarenco, Kevin N. Sheth, Eric E. Smith, John W. Eikelboom, Raed A. Joundi, Karleen Schulze, Lizhen Xu, Laura Heenan, Pablo Colorado, Lars Keller, Eva Muehlhofer, Christoph Neumann, Hardi Mundl, Ashkan Shoamanesh
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 3, 2026, 11:21Thrombotic Microangiopathies: From Clinical Syndrome to Molecularly Targeted Therapy
-
Sep 3, 2026, 10:56Elias Othman: Can an Enzyme Involved in Cell Signaling Become a Target for Antithrombotic Drug Discovery?
-
Sep 3, 2026, 10:42Jared Griffard: Hemorrhagic Shock and Component Blood Transfusion
-
Sep 3, 2026, 10:31Alan Nurden: Comparing Antiplatelet and Antithrombin Therapies in Coronary Microcirculation
-
Sep 3, 2026, 08:53Jamie’s Journey Through a Decade with Immune Thrombocytopenia – ITP Support Association
-
Sep 3, 2026, 08:00Beth Meneley: When Transfusion Is Not an Option – HBOT for Exceptional Blood Loss Anemia
-
Sep 3, 2026, 06:27Seyed Mehrab Safdari: Unmasking Factor VII Padua to Prevent Unnecessary Therapy and Thrombotic Risk
-
Sep 3, 2026, 04:09Pedro Perez: Are We Entering a New Era in the Treatment of Intermediate-High-Risk PE?
-
Sep 3, 2026, 04:01Marianne Yee: Supporting Families and Transformative Therapies in Sickle Cell Disease